MarketCap
Facebook
X
Telegram
Mesoblast Limited Operating Expenses | MESO
Annual Operating Expenses Mesoblast Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 86.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 86.7 M | 86.7 M | 86.7 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
12.8 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
292 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
201 M | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
92.7 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
334 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
109 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
108 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
122 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
88.7 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
96.8 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
110 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
101 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
62.1 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
385 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
98.4 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
101 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
9.73 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
53.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
156 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
122 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
100 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
70.8 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
56.3 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
560 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
211 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
35.1 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
228 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
121 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
57.1 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
88.8 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
103 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
495 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
22.7 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
61.4 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
44.4 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
38.7 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
2.04 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
46.3 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
772 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
33 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
42 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
10.6 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
11.7 M | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
74.6 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
76.5 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
43.4 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
42.5 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
42.6 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
159 M | - | 1.02 % | $ 90.8 M | Britain |